Literature DB >> 8557071

Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992.

Y M al-Gahtani1, H E el Bushra, S M al-Qarawi, A A al-Zubaidi, R E Fontaine.   

Abstract

During March and April of 1992, the health surveillance system began detecting increasing numbers of cases of meningococcal disease (MCD) in the Islamic holy city of Makkah (Mecca). We identified 102 bacteriologically confirmed cases (CC) and 80 suspected cases (SC) of MCD. Neisseria meningitidis was identified as Group A, III-1 clone. The ratio of male:female cases was 2.9:1. All age groups of males were affected. There was only one case among women aged 10-30; 50% of the adult female cases were 55 or older. The case-fatality ratio (CFR) was 14.7% among CC. Pakistanis, who comprised about one-third of the CC, had a CFR of 26.7%. Fifty-nine percent of CC were religious visitors. CC in residents were most common in persons living near the Holy Mosque (Haram), where the carriage rate reached 86%. A mass vaccination program against MCD was instituted, using AC bivalent meningococcal vaccine (MCV). An abrupt drop, from a mean of 15 CC per week to 2 CC per week (only in visitors), coincided with vaccinating 600,000 persons over 2 weeks. Makkah residents who had been vaccinated against MCD were less likely to have contracted MCD (OR = 0.17, 95% CI: 0.06-0.50). MCV was of no significant protective value if it had been administered 5 years before the outbreak. The main reason for not being vaccinated as stated by both cases (71%) and controls (45%) was not knowing about the disease. The age and sex differences probably relate to differences in exposures to crowded conditions. Health education should illuminate the seriousness of the disease and the importance of vaccination.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557071      PMCID: PMC2271597          DOI: 10.1017/s0950268800058556

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  7 in total

1.  Reply: Meningitis in children in Elmadina ElMunowara.

Authors:  E O El-Amin
Journal:  Ann Saudi Med       Date:  1992-05       Impact factor: 1.526

2.  Intercontinental spread of an epidemic group A Neisseria meningitidis strain.

Authors:  P S Moore; M W Reeves; B Schwartz; B G Gellin; C V Broome
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

3.  Features of a large epidemic of group A meningococcal meningitis in Khartoum, Sudan in 1988.

Authors:  M A Salih; H S Ahmed; Z A Karrar; I Kamil; K A Osman; H Palmgren; Y Hofvander; P Olcén
Journal:  Scand J Infect Dis       Date:  1990

4.  Epidemic group A meningococcal disease in Haj pilgrims.

Authors:  V M Novelli; R G Lewis; S T Dawood
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

5.  Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy.

Authors:  N Binkin; J Band
Journal:  Lancet       Date:  1982-08-07       Impact factor: 79.321

6.  Group A meningococcal carriage in travelers returning from Saudi Arabia.

Authors:  P S Moore; L H Harrison; E E Telzak; G W Ajello; C V Broome
Journal:  JAMA       Date:  1988-11-11       Impact factor: 56.272

7.  Control of epidemic group A meningococcal meningitis in Nepal.

Authors:  S L Cochi; L E Markowitz; D D Joshi; R C Owens; D H Stenhouse; D N Regmi; R P Shrestha; I Lacharya; M Manandhar; V L Gurubacharya
Journal:  Int J Epidemiol       Date:  1987-03       Impact factor: 7.196

  7 in total
  25 in total

Review 1.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

2.  Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles.

Authors:  N Bharti; H Broutin; R F Grais; M J Ferrari; A Djibo; A J Tatem; B T Grenfell
Journal:  Epidemiol Infect       Date:  2011-10-05       Impact factor: 2.451

Review 3.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

4.  Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.

Authors:  Hani Jokhdar; Ray Borrow; Abdulrazaq Sultan; Mousaed Adi; Christine Riley; Emily Fuller; David Baxter
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

5.  Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.

Authors:  Mohamed Khalil; Yagob Al-Mazrou; Helen Findlow; Helen Chadha; Valerie Bosch Castells; David R Johnson; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2012-08-01

6.  Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.

Authors:  Jean-François Aguilera; Anne Perrocheau; Christine Meffre; Susan Hahné
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

7.  Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts.

Authors:  Annelies Wilder-Smith; Timothy M S Barkham; Sindhu Ravindran; Arul Earnest; Nicholas I Paton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

8.  Absence of Neisseria meningitidis W-135 electrophoretic Type 37 during the Hajj, 2002.

Authors:  Annelies Wilder-Smith; Timothy M S Barkham; Suok Kai Chew; Nicholas I Paton
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

9.  Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America.

Authors:  R Abad; E L López; R Debbag; J A Vázquez
Journal:  Epidemiol Infect       Date:  2014-05-15       Impact factor: 4.434

10.  Serogroup W-135 meningococcal disease during the Hajj, 2000.

Authors:  Jairam R Lingappa; Abdullah M Al-Rabeah; Rana Hajjeh; Tajammal Mustafa; Adel Fatani; Tami Al-Bassam; Amira Badukhan; Abdulhafiz Turkistani; Sahar Makki; Nassen Al-Hamdan; Mohamed Al-Jeffri; Yaqoub Al Mazrou; Bradley A Perkins; Tonja Popovic; Leonard W Mayer; Nancy E Rosenstein
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.